Neuroimmune basis of methamphetamine toxicity

International Review of Neurobiology

Volumn 118, Issue , 2014, Pages 165-197

  Loftis, Jennifer M ^a,b,c   Janowsky, Aaron ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Addiction; Blood brain barrier; Chemokine; Cytokine; Immunity; Methamphetamine; Neuroinflammation; Psychostimulants

Indexed keywords

IBUDILAST; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHAMPHETAMINE; MN 166; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTRANSMITTER RECEPTOR; NEUROTRANSMITTER TRANSPORTER; TRACE AMINE ASSOCIATED RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT; CYTOKINE; CHEMOKINE RECEPTOR CX3CR1; CHIMERIC MONOCLONAL ANTIBODY 7F9; CYCLOOXYGENASE 2 INHIBITOR; DRUGS USED IN THE TREATMENT OF ADDICTION; EXCITATORY AMINO ACID TRANSPORTER; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; KETOPROFEN; MESSENGER RNA; MINOCYCLINE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROPENTOFYLLINE; RECEPTOR; RECOMBINANT T CELL RECEPTOR LIGAND; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CLINICAL RESEARCH; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG SAFETY; GENE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INNATE IMMUNITY; LONG TERM EXPOSURE; METHAMPHETAMINE DEPENDENCE; MICROGLIA; NEUROIMMUNOLOGY; NEUROMODULATION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TAAR1 GENE; TREATMENT PLANNING; VACCINE PRODUCTION; ANIMAL; DRUG EFFECTS; IMMUNOMODULATION; METABOLISM; ALCOHOLISM; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CX3CR1 GENE; DISEASE ASSOCIATION; GENETIC MODEL; GLIOSIS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IFNG GENE; IL 1BETA GENE; IL 6 GENE; IL 8 GENE; IMMUNE DYSREGULATION; INTRACELLULAR SIGNALING; MEMORY DISORDER; MENTAL DISEASE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; OPIATE ADDICTION; PHAGOCYTOSIS; TNF ALPHA GENE; TOBACCO DEPENDENCE;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOKINES; HUMANS; METHAMPHETAMINE; NEUROIMMUNOMODULATION;

EID: 84906761922     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801284-0.00007-5     Document Type: Chapter

References (153)

1. Abbott N.J., Rönnbäck L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews. Neuroscience 2006, 7:41-53.
2. Abdul Muneer P.M., Alikunju S., Szlachetka A.M., Haorah J. Methamphetamine inhibits the glucose uptake by human neurons and astrocytes: Stabilization by acetyl-L-carnitine. PLoS One 2011, 6:e19258.
3. Achat-Mendes C., Platt D.M., Spealman R.D. Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics 2012, 343:214-224.
4. Aghajanian A., Wittchen E.S., Allingham M.J., Garrett T.A., Burridge K. Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration. Journal of Thrombosis and Haemostasis 2008, 6:1453-1460.
5. Anton R., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., et al. An evaluation of opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Archives of General Psychiatry 2008, 65:135-144.
6. Archibald S.L., Jacobson M.W., Fennema-Notestine C., Ogasawara M., Woods S.P., Letendre S., et al. Functional interactions of HIV-infection and methamphetamine dependence during motor programming. Psychiatry Research 2012, 202:46-52.
7. Ares-Santos S., Granado N., Oliva I., O'Shea E., Martin E.D., Colado M.I., et al. Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiology of Disease 2012, 45:810-820.
8. Asanuma M., Miyazaki I., Higashi Y., Tsuji T., Ogawa N. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Annals of the New York Academy of Sciences 2004, 1025:69-75.
9. Asanuma M., Tsuji T., Miyazaki I., Miyoshi K., Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neuroscience Letters 2003, 352:13-16.
10. Babusyte A., Kotthoff M., Fiedler J., Krautwurst D. Biogenic amines activate blood leukocytes via trace amine-associated receptors TAAR1 and TAAR2. Journal of Leukocyte Biology 2013, 93:387-394.
11. Beardsley P.M., Shelton K.L., Hendrick E., Johnson K.W. The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. European Journal of Pharmacology 2010, 637:102-108.
12. Berk M., Dean O., Drexhage H., McNeil J.J., Moylan S., O'Neil A., et al. Aspirin: A review of its neurobiological properties and therapeutic potential for mental illness. BMC Medicine 2013, 11:74.
13. Blednov Y.A., Mayfield R.D., Belknap J., Harris R.A. Behavioral actions of alcohol: Phenotypic relations from multivariate analysis of mutant mouse data. Genes, Brain, and Behavior 2012, 11:424-435.
14. Blednov Y.A., Ponomarev I., Geil C., Bergeson S., Koob G.F., Harris R.A. Neuroimmune regulation of alcohol consumption: Behavioral validation of genes obtained from genomic studies. Addiction Biology 2012, 17:108-120.
15. Bogatcheva N.V., Verin A.D. The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvascular Research 2008, 76:202-207.
16. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., et al. Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:8966-8971.
17. Bowyer J.F., Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006, 60:521-532.
18. Bowyer J.F., Robinson B., Ali S., Schmued L.C. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 2008, 62:193-204.
19. Brown R.C., Mark K.S., Egleton R.D., Huber J.D., Burroughs A.R., Davis T.P. Protection against hypoxia-induced increase in blood-brain barrier permeability: Role of tight junction proteins and NFkappaB. Journal of Cell Science 2003, 116:693-700.
20. Buch S., Yao H., Guo M., Mori T., Mathias-Costa B., Singh V., et al. Cocaine and HIV-1 interplay in CNS: Cellular and molecular mechanisms. Current HIV Research 2012, 10:425-428.
21. Buchacz K., McFarland W., Kellogg T.A., Loeb L., Holmberg S.D., Dilley J., et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS 2005, 19:1423-1424.
22. Buchanan J.B., Sparkman N.L., Johnson R.W. A neurotoxic regimen of methamphetamine exacerbates the febrile and neuroinflammatory response to a subsequent peripheral immune stimulus. Journal of Neuroinflammation 2010, 7:82.
23. Buchanan J.B., Sparkman N.L., Johnson R.W. Methamphetamine sensitization attenuates the febrile and neuroinflammatory response to a subsequent peripheral immune stimulus. Brain, Behavior, and Immunity 2010, 24:502-511.
24. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Molecular Psychiatry 2009, 14:1095-1104.
25. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Molecular Pharmacology 2001, 60:1181-1188.
26. Cadet J.L., Krasnova I.N. Interactions of methamphetamine and HIV: Cellular and molecular mechanisms of toxicity potentiation. Neurotoxicity Research 2007, 112:181-204.
27. Cardona A.E., Pioro E.P., Sasse M.E., Kostenko V., Cardona S.M., Dijkstra I.M., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neuroscience 2006, 9:917-924.
28. Cerny E.H., Cerny T. Vaccines against nicotine. Human Vaccines 2009, 5:200-205.
29. Chana G., Everall I.P., Crews L., Langford D., Adame A., Grant I., et al. Cognitive deficits and degeneration of interneurons in HIV+methamphetamine users. Neurology 2006, 67:1486-1489.
30. Chang L., Cloak C., Patterson K., Grob C., Miller E.N., Ernst T. Enlarged striatum in abstinent methamphetamine abusers: A possible compensatory response. Biological Psychiatry 2005, 57(9):967-974.
31. Chang L., Ernst T., Speck O., Grob C.S. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. The American Journal of Psychiatry 2005, 162:361-369.
32. Chen H., Uz T., Manev H. Minocycline affects cocaine sensitization in mice. Neuroscience Letters 2009, 452:258-261.
33. Cherner M., Suarez P., Casey C., Deiss R., Letendre S., Marcotte T., et al. Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug and Alcohol Dependence 2010, 106:154-163.
34. Cisneros I.E., Ghorpade A. HIV-1, methamphetamine and astrocyte glutamate regulation: Combined excitotoxic implications for neuro-AIDS. Current HIV Research 2012, 10:392-406.
35. Clark K.H., Wiley C.A., Bradberry C.W. Psychostimulant abuse and neuroinflammation: Emerging evidence of their interconnection. Neurotoxicity Research 2013, 23:174-188.
36. Crawford J.T., Roberts D.C., Beveridge T.J. The group II metabotropic glutamate receptor agonist, LY379268, decreases methamphetamine self-administration in rats. Drug and Alcohol Dependence 2013, 132:414-419.
37. Dean O.M., Data-Franco J., Giorlando F., Berk M. Minocycline: Therapeutic potential in psychiatry. CNS Drugs 2012, 26:391-401.
38. Dogra G., Chakravarti A., Kar P., Chawla Y.K. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response. Human Immunology 2011, 72:935-939.
39. Escubedo E., Camarasa J., Chipana C., García-Ratés S., Pubill D. Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: Pharmacological implications. International Review of Neurobiology 2009, 88:121-166.
40. Escubedo E., Chipana C., Pérez-Sánchez M., Camarasa J., Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of alpha7 nicotinic receptors. The Journal of Pharmacology and Experimental Therapeutics 2005, 315:658-667.
41. Escubedo E., Guitart L., Sureda F.X., Jiménez A., Pubill D., Pallàs M., et al. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Research 1998, 814:120-126.
42. Eshleman A.J., Calligaro D.O., Eldefrawi M.E. Allosteric regulation by sodium of the binding of [3H]cocaine and [3H]GBR 12935 to rat and bovine striata. Membrane Biochemistry 1993, 10:129-144.
43. Eshleman A.J., Wolfrum K.M., Hatfield M.G., Johnson R.A., Murphy K.V., Janowsky A. Substituted methcathinones differ in transporter and receptor interactions. Biochemical Pharmacology 2013, 85:1803-1815.
44. Fantegrossi W.E., Ciullo J.R., Wakabayashi K.T., De La Garza R., Traynor J.R., Woods J.H. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008, 151:533-543.
45. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. The Journal of Clinical Investigation 1998, 102:1369-1376.
46. Friend D.M., Keefe K.A. Glial reactivity in resistance to methamphetamine-induced neurotoxicity. Journal of Neurochemistry 2013, 125:566-574.
47. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:336-339.
48. Fuller B.E., Loftis J.M., Rodriguez V.L., McQuesten M.J., Hauser P. Psychiatric and substance use disorders comorbidities in veterans with hepatitis C virus and HIV coinfection. Current Opinion in Psychiatry 2009, 22:401-408.
49. Gavrilin M.A., Mathes L.E., Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. Journal of Neurovirology 2002, 8:240-249.
50. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
51. Gentry W.B., Rüedi-Bettschen D., Owens S.M. Development of active and passive human vaccines to treat methamphetamine addiction. Human Vaccines 2009, 5:206-213.
52. Gołembiowska K., Konieczny J., Wolfarth S., Ossowska K. Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology 2003, 45:484-492.
53. Goniewicz M.L., Delijewski M. Nicotine vaccines to treat tobacco dependence. Human Vaccines & Immunotherapeutics 2013, 9:13-25.
54. Granado N., Ares-Santos S., Oliva I., O'Shea E., Martin E.D., Colado M.I., et al. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiology of Disease 2011, 42:391-403.
55. Granado N., Lastres-Becker I., Ares-Santos S., Oliva I., Martin E., Cuadrado A., et al. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 2011, 59:1850-1863.
56. Gross N.B., Duncker P.C., Marshall J.F. Cortical ionotropic glutamate receptor antagonism protects against methamphetamine-induced striatal neurotoxicity. Neuroscience 2011, 199:272-283.
57. Guilarte T.R., Nihei M.K., McGlothan J.L., Howard A.S. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: Distal axotomy or neuronal plasticity. Neuroscience 2003, 122:499-513.
58. Gupta V., Gupta A., Jafar T., Gupta V., Agrawal S., Srivastava N., et al. Association of TNF-α promoter gene G-308A polymorphism with metabolic syndrome, insulin resistance, serum TNF-α and leptin levels in Indian adult women. Cytokine 2012, 57:32-36.
59. Harms R., Morsey B., Boyer C.W., Fox H.S., Sarvetnick N. Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression. PLoS One 2012, 7:e49897.
60. Hebert M.A., O'Callaghan J.P. Protein phosphorylation cascades associated with methamphetamine-induced glial activation. Annals of the New York Academy of Sciences 2000, 914:238-262.
61. Herrold A.A., Voigt R.M., Napier T.C. mGluR5 is necessary for maintenance of methamphetamine-induced associative learning. European Neuropsychopharmacology 2013, 23:691-696.
62. Hozumi H., Asanuma M., Miyazaki I., Fukuoka S., Kikkawa Y., Kimoto N., et al. Protective effects of interferon-gamma against methamphetamine-induced neurotoxicity. Toxicology Letters 2008, 177:123-129.
63. In S.W., Son E.W., Rhee D.K., Pyo S. Modulation of murine macrophage function by methamphetamine. Journal of Toxicology and Environmental Health. Part A 2004, 67:1923-1937.
64. In S.W., Son E.W., Rhee D.K., Pyo S. Methamphetamine administration produces immunomodulation in mice. Journal of Toxicology and Environmental Health 2005, 68:2133-2145.
65. Jernigan T.L., Gamst A.C., Archibald S.L., Fennema-Notestine C., Mindt M.R., Marcotte T.D., et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. The American Journal of Psychiatry 2005, 162:1461-1472.
66. Kinsey B.M., Jackson D.C., Orson F.M. Anti-drug vaccines to treat substance abuse. Immunology and Cell Biology 2009, 87:309-314.
67. Kosten T., Domingo C., Orson F., Kinsey B. Vaccines against stimulants: Cocaine and MA. British Journal of Clinical Pharmacology 2014, 77:368-374.
68. Kousik S.M., Napier T.C., Carvey P.M. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Frontiers in Pharmacology 2012, 3:121.
69. Kuhn D.M., Francescutti-Verbeem D.M., Thomas D.M. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: Relationship to methamphetamine-induced nerve ending damage. Annals of the New York Academy of Sciences 2006, 1074:31-41.
70. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv 2010, 460:525-542.
71. LaVoie M.J., Card J.P., Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Experimental Neurology 2004, 187:47-57.
72. Lee Y.W., Hennig B., Yao J., Toborek M. Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. Journal of Neuroscience Research 2001, 66:583-591.
73. Letendre S.L., Cherner M., Ellis R.J., Marquie-Beck J., Gragg B., Marcotte T., et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: Biological correlates of disease. AIDS 2005, 19(Suppl. 3):S72-S78.
74. Li Q.Q., Luo Y.X., Sun C.Y., Xue Y.X., Zhu W.L., Shi H.S., et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. Journal of Neurochemistry 2011, 119:1271-1281.
75. Liang H., Wang X., Chen H., Song L., Ye L., Wang S.H., et al. Methamphetamine enhances HIV infection of macrophages. The American Journal of Pathology 2008, 172:1617-1624.
76. Lio D., Caruso C., Di Stefano R., Colonna Romano G., Ferraro D., Scola L., et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Human Immunology 2003, 64:674-680.
77. Loftis J.M., Choi D., Hoffman W., Huckans M.S. Methamphetamine causes persistent immune dysregulation: A cross-species, translational report. Neurotoxicity Research 2011, 20:59-68.
78. Loftis J.M., Huckans M. Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy. Pharmacology & Therapeutics 2013, 139:289-300.
79. Loftis J.M., Matthews A.M., Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: Epidemiology and management. Drugs 2006, 66:155-174.
80. Loftis J.M., Turner E.H. Novel treatment strategies for depression in patients with hepatitis C. Psychosomatics 2010, 51:357-358.
81. Loftis J.M., Wilhelm C.J., Vandenbark A.A., Huckans M. Partial MHC/neuroantigen peptide constructs: A potential neuroimmune-based treatment for methamphetamine addiction. PLoS One 2013, 8:e56306.
82. Lotrich F.E., Loftis J.M., Ferrell R.E., Rabinovitz M., Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis c during interferon-alpha therapy. Journal of Interferon & Cytokine Research 2010, 31(3):331-336.
83. Lu D.Y., Yu W.H., Yeh W.L., Tang C.H., Leung Y.M., Wong K.L., et al. Hypoxia-induced matrix metalloproteinase-13 expression in astrocytes enhances permeability of brain endothelial cells. Journal of Cellular Physiology 2009, 220:163-173.
84. Mahajan S.D., Hu Z., Reynolds J.L., Aalinkeel R., Schwartz S.A., Nair M.P. Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: Implications for HIV-1 pathogenesis. Molecular Diagnosis & Therapy 2006, 10:257-269.
85. Martinez L.R., Mihu M.R., Gacser A., Santambrogio L., Nosanchuk D. Methamphetamine enhances histoplasmosis by immunosuppression of the host. The Journal of Infectious Diseases 2009, 200:131-141.
86. Martins T., Baptista S., Goncalves J., Leal E., Milhazes N., Borges F., et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: Role of tight junction proteins and matrix metalloproteinase-9. Brain Research 2011, 1411:28-40.
87. Mizoguchi H., Takuma K., Fukakusa A., Ito Y., Nakatani A., Ibi D., et al. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology 2008, 196:233-241.
88. Narita M., Miyatake M., Narita M., Shibasaki M., Shindo K., Nakamura A., et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476-2488.
89. Nath A., Geiger J. Neurobiological aspects of human immunodeficiency virus infection: Neurotoxic mechanisms. Progress in Neurobiology 1998, 54:19-33.
90. Nath A., Maragos W.F., Avison M.J., Schmitt F.A., Berger J.R. Acceleration of HIV dementia with methamphetamine and cocaine. Journal of Neurovirology 2001, 7:66-71.
91. Nelson D.A., Tolbert M.D., Singh S.J., Bost K.L. Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes. Journal of Neuroimmunology 2007, 192:21-30.
92. Northrop N.A., Smith L.P., Yamamoto B.K., Eyerman D.J. Regulation of glutamate release by α7 nicotinic receptors: Differential role in methamphetamine-induced damage to dopaminergic and serotonergic terminals. The Journal of Pharmacology and Experimental Therapeutics 2011, 336:900-907.
93. Northrop N.A., Yamamoto B.K. Persistent neuroinflammatory effects of serial exposure to stress and methamphetamine on the blood-brain barrier. Journal of Neuroimmune Pharmacology 2012, 7:951-968.
94. Orson F.M., Kinsey B.M., Singh R.A., Wu Y., Kosten T.R. Vaccines for cocaine abuse. Human Vaccines 2009, 5:194-199.
95. Oxenkrug G., Perianayagam M., Mikolich D., Requintina P., Shick L., Ruthazer R., et al. Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. Journal of Neural Transmission 2011, 118:271-274.
96. Panas M.W., Xie Z., Panas H.N., Hoener M.C., Vallender E.J., Miller G.M. Trace amine associated receptor 1 signaling in activated lymphocytes. Journal of Neuroimmune Pharmacology 2012, 7:866-876.
97. Persidsky Y., Ramirez S.H., Haorah J., Kanmogne G.D. Blood-brain barrier: Structural components and function under physiologic and pathologic conditions. Journal of Neuroimmune Pharmacology 2006, 1:223-236.
98. Potula R., Hawkins B.J., Cenna J.M., Fan S., Dykstra H., Ramierez S.H., et al. Methamphetamine causes mitochondrial oxidative damage in human T lymphocytes leading to functional impairment. Journal of Immunology 2010, 185:2867-2876.
99. Pubill D., Chipana C., Camins A., Pallàs M., Camarasa J., Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicology and Applied Pharmacology 2005, 204:57-68.
100. Ramirez S.H., Potula R., Fan S., Eidem T., Papugani A., Reichenbach N., et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. Journal of Cerebral Blood Flow and Metabolism 2009, 29:1933-1945.
101. Reynolds J.L., Mahajan S.D., Aalinkeel R., Nair B., Sykes D.E., Schwartz S.A. Proteomic analyses of the effects of drugs of abuse on monocyte-derived mature dendritic cells. Immunological Investigations 2009, 38:526-550.
102. Rippeth J.D., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society 2004, 10:1-14.
103. Robson M.J., Turner R.C., Naser Z.J., McCurdy C.R., O'Callaghan J.P., Huber J.D., et al. SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Experimental Neurology 2014, 254:180-189.
104. Saito M., Yamaguchi T., Kawata T., Ito H., Kanai T., Terada M., et al. Effects of methamphetamine on cortisone concentration, NK cell activity and mitogen response of T-lymphocytes in female cynomolgus monkeys. Experimental Animals 2006, 55:477-481.
105. Schwarz J.M., Hutchinson M.R., Bilbo S.D. Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression. The Journal of Neuroscience 2011, 31:17835-17847.
106. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brains of human abusers. The Journal of Neuroscience 2008, 28:5756-5761.
107. Shah A., Silverstein P.S., Singh D.P., Kumar A. Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-κB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. Journal of Neuroinflammation 2012, 9:52.
108. Shen X.Y., Kosten T.A., Lopez A.Y., Kinsey B.M., Kosten T.R., Orson F.M. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug and Alcohol Dependence 2013, 129:41-48.
109. Shin E.J., Duong C.X., Nguyen T.X., Bing G., Bach J.H., Park D.H., et al. PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment. Neurochemistry International 2011, 59:39-50.
110. Shin E.J., Duong C.X., Nguyen X.K., Li Z., Bing G., Bach J.H., et al. Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ. Behavioural Brain Research 2012, 232:98-113.
111. Sinha S., Subramanian S., Proctor T.M., Kaler L.J., Grafe M., Dahan R., et al. A promising therapeutic approach for multiple sclerosis: Recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. The Journal of Neuroscience 2007, 27:12531-12539.
112. Smith K.J., Butler T.R., Prendergast M.A. Inhibition of sigma-1 receptor reduces N-methyl-D-aspartate induced neuronal injury in methamphetamine-exposed and-naive hippocampi. Neuroscience Letters 2010, 13(481):144-148.
113. Smith A.K., Simon J.S., Gustafson E.L., Noviello S., Cubells J.F., Epstein M.P., et al. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Molecular Psychiatry 2012, 17:781-789.
114. Snider S.E., Hendrick E.S., Beardsley P.M. Glial cell modulators attenuate methamphetamine self-administration in the rat. European Journal of Pharmacology 2013, 701:124-130.
115. Snider S.E., Vunck S.A., van den Oord E.J., Adkins D.E., McClay J.L., Beardsley P.M. The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice. European Journal of Pharmacology 2012, 679:75-80.
116. Sriram K., Benkovic S.A., Hebert M.A., Miller D.B., O'Callaghan J.P. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: Key signaling pathway for astrogliosis in vivo?. The Journal of Biological Chemistry 2004, 279:19936-19947.
117. Stevens M.W., Tawney R.L., West C.M., Kight A.D., Henry R.L., Owens S.M., et al. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs 2014, 6:547-555.
118. Subramanian S., Zhang B., Kosaka Y., Burrows G.G., Grafe M.R., Vandenbark A.A., et al. Recombinant T cell receptor ligand treats experimental stroke. Stroke 2009, 40:2539-2545.
119. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. The Journal of Neuroscience 1995, 15:4102-4108.
120. Suzuki S., Kawamata J., Matsushita T., Matsumura A., Hisahara S., Takata K., et al. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats. Journal of Neuroscience Research 2013, 91:462-471.
121. Talloczy Z., Martinez J., Joset D., Ray Y., Gacser A., Toussi S., et al. Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathogens 2008, 4:e28.
122. Tamura S., Morikawa Y., Senba E. Localization of oncostatin M receptor beta in adult and developing CNS. Neuroscience 2003, 119:991-997.
123. Taylor M.J., Letendre S.L., Schweinsburg B.C., Alhassoon O.M., Brown G.G., Gongvatana A., et al. Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. Journal of the International Neuropsychological Society 2004, 10:110-113.
124. Theodore S., Cass W.A., Maragos W.F. Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Experimental Neurology 2006, 199:490-498.
125. Theodore S., Cass W.A., Nath A., Steiner J., Young K., Maragos W.F. Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. Neurobiology of Disease 2006, 23:663-668.
126. Theodore S., Stolberg S., Cass W.A., Maragos W.F. Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Annals of the New York Academy of Sciences 2006, 1074:178-190.
127. Thio C.L., Goedert J.J., Mosbruger T., Vlahov D., Strathdee S.A., O'Brien S.J., et al. An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes and Immunity 2004, 5:294-300.
128. Thomas D.M., Angoa Pérez M., Francescutti-Verbeem D.M., Shah M.M., Kuhn D.M. The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum. Journal of Neurochemistry 2010, 115:595-605.
129. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. Journal of Neurochemistry 2008, 106:696-705.
130. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. Journal of Neurochemistry 2008, 105:605-616.
131. Thomas D.M., Francescutti-Verbeem D.M., Liu X., Kuhn D.M. Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment-an oligonucleotide microarray approach. Journal of Neurochemistry 2004, 88:380-393.
132. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. The Journal of Pharmacology and Experimental Therapeutics 2004, 311:1-7.
133. Vaarmann A., Gandhi S., Abramov A.Y. Dopamine induces Ca2+ signaling in astrocytes through reactive oxygen species generated by monoamine oxidase. The Journal of Biological Chemistry 2010, 285:25018-25023.
134. Vandenbark A.A., Rich C., Mooney J., Zamora A., Wang C., Huan J., et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. Journal of Immunology 2003, 171:127-133.
135. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. The Journal of Neuroscience 2001, 21:9414-9418.
136. Wang C., Gold B.G., Kaler L.J., Yu X., Afentoulis M.E., Burrows G.G., et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. Journal of Neurochemistry 2006, 98:1817-1827.
137. Wang Q., Shin E.J., Nguyen X.K., Li Q., Bach J.H., Bing G., et al. Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. Journal of Neuroinflammation 2012, 9:124.
138. Wasik A.M., Millan M.J., Scanlan T., Barnes N.M. Gordon evidence for functional trace amine associated receptor-1 in normal and malignant B cells. Leukemia Research 2012, 36:245-249.
139. Weber E., Morgan E.E., Iudicello J.E., Blackstone K., Grant I., Ellis R.J., et al. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. Journal of Neurovirology 2013, 19:65-74.
140. Wey S.P., Wu H.Y., Chang F.C., Jan T.R. Methamphetamine and diazepam suppress antigen-specific cytokine expression and antibody production in ovalbumin-sensitized BALB/c mice. Toxicology Letters 2008, 181:157-162.
141. Whitney N.P., Eidem T.M., Peng H., Huang Y., Zheng J.C. Inflammation mediates varying effects in neurogenesis: Relevance to the pathogenesis of brain injury and neurodegenerative disorders. Journal of Neurochemistry 2009, 108:1343-1359.
142. Wilhelm C. J., Hashimoto J. G., Roberts M. L., Loftis J. M., Wiren K. M. (2014) Distinct glucocorticoid signaling associated with ethanol-induced inflammotoxicity. 37th annual research society on alcoholism (RSA) scientific meeting, June 2014 (abstract accepted).
143. Wilhelm C.J., Johnson R.A., Lysko P.G., Eshleman A.J., Janowsky A. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. The Journal of Pharmacology and Experimental Therapeutics 2004, 310:1142-1151.
144. Wires E.S., Alvarez D., Dobrowolski C., Wang Y., Morales M., Karn J., et al. Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. Journal of Neurovirology 2012, 18:400-410.
145. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: Classical and emerging mechanisms. Annals of the New York Academy of Sciences 2010, 1187:101-121.
146. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. Journal of Neuroimmune Pharmacology 2008, 3:203-217.
147. Yan Y., Nitta A., Koseki T., Yamada K., Nabeshima T. Dissociable role of tumor necrosis factor alpha gene deletion in methamphetamine self-administration and cue-induced relapsing behavior in mice. Psychopharmacology 2012, 221:427-436.
148. Ye L., Peng J.S., Wang X., Wang Y.J., Luo G.X., Ho W.Z. Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. Journal of Viral Hepatitis 2008, 15:261-270.
149. Yu Q., Zhang D., Walston M., Zhang J., Liu Y., Watson R.R. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. International Immunopharmacology 2002, 2:951-962.
150. Zhang X.Q., Cui Y., Cui Y., Chen Y., Na X.D., Chen F.Y., et al. Activation of p38 signaling in the microglia in the nucleus accumbens contributes to the acquisition and maintenance of morphine-induced conditioned place preference. Brain, Behavior, and Immunity 2012, 26:318-325.
151. Zhang L., Kitaichi K., Fujimoto Y., Nakayama H., Shimizu E., Iyo M., et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2006, 30:1381-1393.
152. Zhu J.P., Xu W., Angulo J.A. Methamphetamine-induced cell death: Selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience 2006, 140:607-622.
153. Zorick T., Nestor L., Miotto K., Sugar C., Hellemann G., Scanlon G., et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010, 105:1809-1818.